Polymer microparticles offer a highly versatile platform for precision delivery through their tunable surface functionalization, biocompatible matrices, and controlled-release kinetics. Key challenges in scaling polymer particle systems from early-stage R&D to commercial manufacturing include preserving critical quality attributes such as particle size distribution, encapsulation efficiency, and release profile. At nanoComposix, we help bridge this gap by partnering with you to develop formulations engineered for both performance and manufacturability.
In this application note, we describe how controlled-release profiles can be tailored by tuning key polymer properties, with a focus on PLGA-based systems. Using rapamycin as a model active pharmaceutical ingredient (API), we walk through the formulation strategy to achieve target controlled-release profiles.